-
1
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335-42.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
-
2
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
-
3
-
-
84867047384
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
-
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3499-3506
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
Prenen, H.4
Prausova, J.5
Macarulla, T.6
-
4
-
-
84906903314
-
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial
-
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384:665-73.
-
(2014)
Lancet
, vol.384
, pp. 665-673
-
-
Garon, E.B.1
Ciuleanu, T.E.2
Arrieta, O.3
Prabhash, K.4
Syrigos, K.N.5
Goksel, T.6
-
5
-
-
0030460424
-
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
-
Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
-
(1996)
Cell
, vol.87
, pp. 1161-1169
-
-
Davis, S.1
Aldrich, T.H.2
Jones, P.F.3
Acheson, A.4
Compton, D.L.5
Jain, V.6
-
6
-
-
15144358851
-
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
-
Maisonpierre PC, Suri C, Jones PF, Bartunkova S,Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
-
(1997)
Science
, vol.277
, pp. 55-60
-
-
Maisonpierre, P.C.1
Suri, C.2
Jones, P.F.3
Bartunkova, S.4
Wiegand, S.J.5
Radziejewski, C.6
-
7
-
-
60749096085
-
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
-
Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-77.
-
(2009)
Nat Rev Mol Cell Biol
, vol.10
, pp. 165-177
-
-
Augustin, H.G.1
Koh, G.Y.2
Thurston, G.3
Alitalo, K.4
-
8
-
-
84875807200
-
The complex role of angiopoietin-2 in the angiopoietin- tie signaling pathway
-
Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin- tie signaling pathway. Cold SpringHarb Perspect Med2012;2:a006550.
-
(2012)
Cold SpringHarb Perspect Med
, vol.2
, pp. a006550
-
-
Thurston, G.1
Daly, C.2
-
9
-
-
0030480322
-
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
-
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
-
(1996)
Cell
, vol.87
, pp. 1171-1180
-
-
Suri, C.1
Jones, P.F.2
Patan, S.3
Bartunkova, S.4
Maisonpierre, P.C.5
Davis, S.6
-
10
-
-
0034036689
-
Angiopoietin- 1 protects the adult vasculature against plasma leakage
-
Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin- 1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
-
(2000)
Nat Med
, vol.6
, pp. 460-463
-
-
Thurston, G.1
Rudge, J.S.2
Ioffe, E.3
Zhou, H.4
Ross, L.5
Croll, S.D.6
-
11
-
-
0033601357
-
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
-
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
-
(1999)
Science
, vol.286
, pp. 2511-2514
-
-
Thurston, G.1
Suri, C.2
Smith, K.3
McClain, J.4
Sato, T.N.5
Yancopoulos, G.D.6
-
12
-
-
73949105871
-
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models
-
Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9:145-56.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 145-156
-
-
Brown, J.L.1
Cao, Z.A.2
Pinzon-Ortiz, M.3
Kendrew, J.4
Reimer, C.5
Wen, S.6
-
13
-
-
84871989305
-
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition
-
Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73:108-18.
-
(2013)
Cancer Res
, vol.73
, pp. 108-118
-
-
Daly, C.1
Eichten, A.2
Castanaro, C.3
Pasnikowski, E.4
Adler, A.5
Lalani, A.S.6
-
14
-
-
73649112748
-
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels
-
Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009;175:2159-70.
-
(2009)
Am J Pathol
, vol.175
, pp. 2159-2170
-
-
Falcon, B.L.1
Hashizume, H.2
Koumoutsakos, P.3
Chou, J.4
Bready, J.V.5
Coxon, A.6
-
15
-
-
60549103097
-
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth
-
Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009;69:1324-33.
-
(2009)
Cancer Res
, vol.69
, pp. 1324-1333
-
-
Nasarre, P.1
Thomas, M.2
Kruse, K.3
Helfrich, I.4
Wolter, V.5
Deppermann, C.6
-
16
-
-
7944220649
-
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin- 2
-
Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin- 2. Cancer Cell 2004;6:507-16.
-
(2004)
Cancer Cell
, vol.6
, pp. 507-516
-
-
Oliner, J.1
Min, H.2
Leal, J.3
Yu, D.4
Rao, S.5
You, E.6
-
17
-
-
74549172848
-
Angiopoietin- 2 promotes disease progression of neuroendocrine tumors
-
Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, et al. Angiopoietin- 2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010;16:420-9.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 420-429
-
-
Detjen, K.M.1
Rieke, S.2
Deters, A.3
Schulz, P.4
Rexin, A.5
Vollmer, S.6
-
18
-
-
63149188174
-
Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma
-
Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009;15: 1384-92.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1384-1392
-
-
Helfrich, I.1
Edler, L.2
Sucker, A.3
Thomas, M.4
Christian, S.5
Schadendorf, D.6
-
19
-
-
34447525629
-
Serum angiopoietin-2 as a clinical marker for lung cancer
-
Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007;132: 200-6.
-
(2007)
Chest
, vol.132
, pp. 200-206
-
-
Park, J.H.1
Park, K.J.2
Kim, Y.S.3
Sheen, S.S.4
Lee, K.S.5
Lee, H.N.6
-
20
-
-
0031737425
-
Cell type-specific expression of angiopoietin- 1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis
-
Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin- 1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
-
(1998)
Am J Pathol
, vol.153
, pp. 1459-1466
-
-
Stratmann, A.1
Risau, W.2
Plate, K.H.3
-
21
-
-
0032939205
-
Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma
-
Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-5.
-
(1999)
J Clin Invest
, vol.103
, pp. 341-345
-
-
Tanaka, S.1
Mori, M.2
Sakamoto, Y.3
Makuuchi, M.4
Sugimachi, K.5
Wands, J.R.6
-
22
-
-
84859880607
-
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma
-
Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2290-2300
-
-
Llovet, J.M.1
Pena, C.E.2
Lathia, C.D.3
Shan, M.4
Meinhardt, G.5
Bruix, J.6
-
23
-
-
84907399835
-
Serum angiopoietin-2 and soluble VEGFR-2 levels predictmalignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer
-
Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predictmalignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer 2014;14:696.
-
(2014)
BMC Cancer
, vol.14
, pp. 696
-
-
Sallinen, H.1
Heikura, T.2
Koponen, J.3
Kosma, V.M.4
Heinonen, S.5
Yla-Herttuala, S.6
-
25
-
-
70249114453
-
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
-
Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. JClin Oncol 2009;27:3557-65.
-
(2009)
JClin Oncol
, vol.27
, pp. 3557-3565
-
-
Herbst, R.S.1
Hong, D.2
Chap, L.3
Kurzrock, R.4
Jackson, E.5
Silverman, J.M.6
-
26
-
-
84956792410
-
A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors
-
Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, et al. A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2014;32:5s.
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Dowlati, A.1
Vlahovic, G.2
Natale, R.B.3
Rasmussen, E.4
Singh, I.5
Hwang, Y.C.6
-
29
-
-
0036156877
-
Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor
-
Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, SaleemMA,Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 2002; 13:544-50.
-
(2002)
J Am Soc Nephrol
, vol.13
, pp. 544-550
-
-
Satchell, S.C.1
Harper, S.J.2
Tooke, J.E.3
Kerjaschki, D.4
Saleem, M.A.5
Mathieson, P.W.6
-
30
-
-
34547628176
-
Podocytespecific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia
-
Davis B, Dei Cas A, Long DA, White KE, Hayward A, Ku CH, et al. Podocytespecific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 2007;18:2320-9.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 2320-2329
-
-
Davis, B.1
Dei Cas, A.2
Long, D.A.3
White, K.E.4
Hayward, A.5
Ku, C.H.6
-
31
-
-
59949085812
-
Roles of angiopoietins in kidney development and disease
-
Woolf AS, Gnudi L, Long DA. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 2009;20:239-44.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 239-244
-
-
Woolf, A.S.1
Gnudi, L.2
Long, D.A.3
-
32
-
-
13344284635
-
A reversible posterior leukoencephalopathy syndrome
-
Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
-
(1996)
N Engl J Med
, vol.334
, pp. 494-500
-
-
Hinchey, J.1
Chaves, C.2
Appignani, B.3
Breen, J.4
Pao, L.5
Wang, A.6
-
33
-
-
84856029091
-
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents
-
Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011;6:253-8.
-
(2011)
Target Oncol
, vol.6
, pp. 253-258
-
-
Tlemsani, C.1
Mir, O.2
Boudou-Rouquette, P.3
Huillard, O.4
Maley, K.5
Ropert, S.6
-
34
-
-
0035132684
-
Prevalence of cerebral white matter lesions in elderly people: A population based magnetic resonance imaging study. The Rotterdam Scan Study
-
de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The RotterdamScan Study. J Neurol Neurosurg Psychiatry 2001;70:9-14.
-
(2001)
J Neurol Neurosurg Psychiatry
, vol.70
, pp. 9-14
-
-
De Leeuw, F.E.1
De Groot, J.C.2
Achten, E.3
Oudkerk, M.4
Ramos, L.M.5
Heijboer, R.6
-
35
-
-
1942456802
-
The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals
-
Wen W, Sachdev P. The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals. Neuroimage 2004;22:144-54.
-
(2004)
Neuroimage
, vol.22
, pp. 144-154
-
-
Wen, W.1
Sachdev, P.2
-
36
-
-
84962300276
-
Clinical and biologic effects of the angiopoietin 1/2 neutralizing peptibody, trebananib (AMG 386), in acute myeloid leukemia patients
-
Orlando, FL (abstract 2701)
-
Wang ES, Fetterly G, Brady W, Tan W, Greene J, Gaudy A, et al. Clinical and biologic effects of the angiopoietin 1/2 neutralizing peptibody, trebananib (AMG 386), in acute myeloid leukemia patients. American Society of Hematology (ASH) 55th Annual Meeting, Orlando, FL (abstract 2701).
-
American Society of Hematology (ASH) 55th Annual Meeting
-
-
Wang, E.S.1
Fetterly, G.2
Brady, W.3
Tan, W.4
Greene, J.5
Gaudy, A.6
-
37
-
-
84902811306
-
A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin- 2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies
-
Papadopoulos KP, Graham DM, Tolcher AW, Razak ARA, Patnaik A, Bedard PL, et al. A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin- 2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies. J Clin Oncol 2014;32:5s.
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Papadopoulos, K.P.1
Graham, D.M.2
Tolcher, A.W.3
Razak, A.R.A.4
Patnaik, A.5
Bedard, P.L.6
|